RNF214-TEAD-YAP 信号轴通过 TEAD 泛素化促进肝细胞癌进展。
The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.
机构信息
State Key Laboratory for Diagnosis and Treatment of Infectious Disease, and National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China.
Life Sciences Institute, Zhejiang University, Hangzhou, 310058, Zhejiang, China.
出版信息
Nat Commun. 2024 Jun 11;15(1):4995. doi: 10.1038/s41467-024-49045-y.
RNF214 is an understudied ubiquitin ligase with little knowledge of its biological functions or protein substrates. Here we show that the TEAD transcription factors in the Hippo pathway are substrates of RNF214. RNF214 induces non-proteolytic ubiquitylation at a conserved lysine residue of TEADs, enhances interactions between TEADs and YAP, and promotes transactivation of the downstream genes of the Hippo signaling. Moreover, YAP and TAZ could bind polyubiquitin chains, implying the underlying mechanisms by which RNF214 regulates the Hippo pathway. Furthermore, RNF214 is overexpressed in hepatocellular carcinoma (HCC) and inversely correlates with differentiation status and patient survival. Consistently, RNF214 promotes tumor cell proliferation, migration, and invasion, and HCC tumorigenesis in mice. Collectively, our data reveal RNF214 as a critical component in the Hippo pathway by forming a signaling axis of RNF214-TEAD-YAP and suggest that RNF214 is an oncogene of HCC and could be a potential drug target of HCC therapy.
RNF214 是一种研究较少的泛素连接酶,其生物学功能或蛋白质底物知之甚少。在这里,我们表明 Hippo 通路中的 TEAD 转录因子是 RNF214 的底物。RNF214 在 TEADs 的保守赖氨酸残基上诱导非蛋白水解泛素化,增强 TEADs 与 YAP 之间的相互作用,并促进 Hippo 信号下游基因的转录激活。此外,YAP 和 TAZ 可以结合多泛素链,这暗示了 RNF214 调节 Hippo 通路的潜在机制。此外,RNF214 在肝细胞癌(HCC)中过表达,与分化状态和患者生存呈负相关。一致地,RNF214 促进肿瘤细胞增殖、迁移和侵袭,以及 HCC 小鼠肿瘤发生。总之,我们的数据揭示了 RNF214 通过形成 RNF214-TEAD-YAP 信号轴作为 Hippo 通路的关键组成部分,并表明 RNF214 是 HCC 的癌基因,可能成为 HCC 治疗的潜在药物靶点。
相似文献
Cell Death Dis. 2024-7-5
Int J Mol Sci. 2024-8-5
引用本文的文献
PLoS Pathog. 2025-4-22
MedComm (2020). 2025-3-10
本文引用的文献
Nat Commun. 2023-11-23
Signal Transduct Target Ther. 2022-11-8
Clin Sci (Lond). 2022-2-11
Nat Rev Gastroenterol Hepatol. 2022-5
Cancers (Basel). 2021-12-10
Semin Cancer Biol. 2022-10
Annu Rev Pathol. 2021-1-24